Open AccesshENT‐1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
Author(s) -
Meijer Laura L.,
Puik Jisce R.,
Peters Godefridus J.,
Kazemier Geert,
Giovannetti Elisa
Publication year - 2016
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2016-0262
Subject(s) - gemcitabine , medicine , biomarker , oncology , adjuvant , intrahepatic cholangiocarcinoma , protein expression , cancer , gene , biochemistry , chemistry
In this letter to the editor, the authors discuss the use of human equilibrative nucleoside transporter 1 (hENT‐1) as a biomarker in patients with cholangiocarcinoma. They encourage standardization of techniques to evaluation expression of proteins such as hENT‐1 and suggest additional studies investigating the active metabolites of gemcitabine, the use of liquid biopsies, and improved statistical methods.